Staurosporine, 2, an indolo (2,3-a) carbazole alkaloid, was first isolated in 1977 by S. Omura and co-workers from Streptomyces sp. AM-22821}, later reclassified as Saccharothrix sp. Its structure and relative stereochemistry were determined by X-ray crystallographic analysis2 '3) and by XH and 13C NMRstudies4). The absolute stereochemistry could only recently be established5). The latter publication also mentions its many biological activities which were subsequently detected over a period of 10 years, such as antimicrobial, hypotensive, cell cytotoxic activities and inhibition of platelet aggregation and protein kinase C. In our ownstudies wewere particularly interested in its potent activity against the latter enzymewhich plays a key role in cellular signal transduction6) and is therefore a promising target for antitumor compounds. Since staurosporine itself does not show the desired subtype specificity a number of semisynthetic derivatives were synthesized and tested in an appropriate test panel.
Among these derivatives the 4' 7V-benzoyl derivative CGP 41 251 , 3, exhibited the desired specificity and was selected for further development as an antitumor drug7~9).
In order to improve the preparative access to the starting material staurosporine 2 we initiated a program of strain and process development. The producing strain was subjected to a mutagenic treatment. The isolated mutants were tested for improved productivity and for the production of novel intermediates. Such intermediates from blocked mutants could provide valuable information on the biosynthetic pathway of staurosporine only the first steps of which have been investigated to date4'10). This paper deals with the isolation and characterization of 3'-demethoxy-3'-hydroxystaurosporine 1 (CGP 58 546), which was shown to be an intermediate in the biosynthetic pathway. In addition, the interesting in vitro activity of the newmetabolite and the isolation of the producing mutant strain Ml4 (DSM8325) will also be described.
Materials and Methods

Microorganism
The origin of our staurosporine-producing strain Streptomyces longisporoflavus R19 was reported before11}. The selected colony R19/col 15 was picked from a series of cultures on agar plates and used as the parental strain for the mutation program. The mutant strain producing 3'-demethoxy-3'- survival curve, irradiation in the dark was carried out during 50 seconds to obtain 0.01 to 0.1% of surviving spores12). The irradiated spore suspension was diluted 100-fold with phosphate buffer of pH 7.0, stored in the dark for one day at room temperature, plated on SPA and incubated for 5^7 days. The incubated agar cultures were replica-plated on MAand SPA plates. After 4 days of incubation the replicas were compared to the master plates. All colonies differing in shape, color and/or size on MAwere isolated, cultivated in shake flasks and examined with respect to metabolite production by TLC and HPLC. Selected colonies were transferred to 50-ml Erlenmeyer flasks containing 10ml of medium NL 148 and incubated for 3 days on a rotary shaker with an agitation of 220 rpm. One ml of this first preculture was used to seed a second one which was cultivated for 2 days under the same conditions. One ml of this seed was used to inoculate 20ml of production mediumNL3 in 100-ml shake flasks. Incubation was carried out at 28°d uring 5 days.
Analytical Methods
For TLCanalysis culture broth samples were extracted with methylene chloride or ethyl acetate. Aliquots of the organic phase (25 /A) were deposited on silica gel plates. Inocula grown on SPA slants were transferred into 100-ml Erlenmeyer flasks containing 20ml of medium NL 148 and incubated for 3 days on a rotatory shaker (220 rpm). 0.5~1 ml of this seed culture was then used to inoculate 20ml of the same mediumin 100-ml Erlenmeyer flasks and cultured for 2 days at 220rpm. 1~2ml of the second seed culture were then transferred to 500-ml shake flasks containing 100ml of fermentation mediumNL3 and incubated under the same conditions for 5 days. b) Co fermentation: precultures of mutant strain DSM 8325 and mutant strain Ml3 producing the aglycone 4 as the only metabolite were prepared separately as described above. One ml of each seed culture was transferred to 500-ml shake flasks containing 100ml of mediumNL3. The pattern of metabolites was analyzed after 5 days of incubation at 220rpm. c) 30-liter fermenters: the fermentation was preceded by 2 inoculum stages (initial pH of about 7.6), whereas the production fermentation was performed at pH values ranging from 6.0 to 7.0. For the first preculture the contents of a cryo ampoule or a loopful of the mutant strain grown on agar were transferred to 50-ml
Erlenmeyer flasks containing 10ml of medium NL 148. After incubation at 220rpm for 48hours 1ml of this culture was used to inoculate 100ml of the same medium in 500-ml flasks with 1 baffle. The flasks were incubated for 48hours at 250rpm. A second preculture was prepared by using 25ml of the first preculture for the inoculation of 500ml of NL 148 in 2-liter Erlenmeyer flasks with 4 baffles. After 48 hours at 120rpm 600ml of this second preculture were used to inoculate 30 liters of medium NL 3 in a MBRfermenter. The production fermentation was run for a period of 1 17 hours (aeration, 1 liter/1 liter/minute; agitation, 600rpm; head space pressure 0.5 bar). The stirring velocity was controlled in order to maintain dissolved oxygen above 30%. No pH adjustment was made during the fermentation. The production of secondary metabolites was periodically analyzed by HPLC.
Strain Preservation
Cultures of the mutant strains were stored at -80°C.
A 50-ml Erlenmeyer flask containing 10ml of medium NL 148 was inoculated with 1 ml of the first preculture obtained as described above. After growth for 2 days at 28°C and 220rpm aliquots of 1.5ml were stored in cryo-ampoules.
Spectroscopy
The following instruments were used in this study: NMR Varian VXR-400S and Varian Unity 500, UV/VIS yellow to brown mycelium on SPA, whereas the parental strain R19/col 15 formed a grey colored mature spore mass. Chromatographic analysis by TLC revealed the presence of only one major metabolite, 1, which was more polar than staurosporine. In the HPLC/diode array detection system it showed one major peak with a UV-spectrum almost superimposable over that of staurosporine. Therefore, this mutant was further investigated with first priority.
In liquid medium NL 148, mutant M14 formed small pellets with a diameter of up to 3mm. The titer of the new metabolite in mediumNL 3 amounted to 55 mg/liter after 4 days of culture in fermenters and could be significantly increased by stepwise optimization of the composition of the medium. The metabolite pattern was unchanged after 10 or more successive fermentations confirming the genetic stability of this mutant.
Isolation and Purification of Metabolite 1 a) From shake flask cultures: 1.5 liter of the whole fermentation broth was vigorously stirred with 2 liters of methylene chloride. The extracted cell material was removed by filtration using Hyflo (diatomaceous earth) as filter aid. The aqueous layer of the clear filtrate was separated and subjected to further extraction with 2liters of ethyl acetate. The combined organic extracts were washed with a small volume of water, dried over anhydrous sodium sulfate and evaporated to dryness. Crystallization of the residue from a small volume of ethyl acetate yielded pure 1 (30mg) in the form of pale yellowish crystals. b) From fermenter culture: Culture broths from 3 different fermenter runs were combined (77liters). The whole broth was vigorously stirred with twice its volume of ethyl acetate. After addition of Hyflo (10 kg) the suspension was filtered and the filter cake washed with additional ethyl acetate (30 liters). The organic phase was washed with saturated brine and the solvent evaporated in vacuo. The crude extract (55.5 g) was triturated with /2-heptane (1 liter) to remove 44.84g of a thin oil. The insoluble residue (10.57g) was dissolved in a minimum amount of methylene chloride.
A first crop of crystals which precipitated spontaneously was separated, dissolved in methanol, treated with active charcoal and filtered. The clear filtrate was concentrated and recrystallized from ethyl acetate. The mother liquor was combined with the previously obtained mother liquor from the spontaneously formed crystals in methylene chloride and the pooled material further purified by column chromatography on silica gel (Si 60 Merck, particle size, 15~25 /i; 1 liter). The desired product was eluted with methylene chloride -methanol (95 : 5). Crystallization and repeated chromatography of mother liquors and impure fractions eventually yielded a second and a third crops of crystals from ethyl acetate. The combined crystallizates were recrystallized from ethyl acetate, giving a total yield of 1.13g of pale yellow crystals of pure compound (from 77 liters of culture broth). Structure Elucidation of Compound1 Thestructure elucidation of the newmetabolite from mutant strain Ml4 was based on results of MS-and NMRspectroscopy. The signals of the *H and 13C NMR spectra (listed in Table 1 ) were very similar to those of staurosporine4'11}. The major difference was the lack of the OCH3group documented by a missing singlet signal at 3.32ppm in the XH NMRand of the primary carbon signal at 57.2ppm in the 13C NMR.In addition, the signal for the C-atom in position 3' was significantly shifted down field from 82.7 to 68.9ppm. The assumed elemental composition C27H24N4O3 of 1 was confirmed by a positive mode high resolution FAB-MSwhich gave a molecular weight of 452.517. Final proof of the structure of 1 was provided by the bioconversion 303 experiments described below.
Results of Bioconversion Experiments The first bioconversions were carried out with another blocked mutant, Ml3, which produced the aglycone K-252c 4 as the only detectable metabolite13). Cultures of this strain converted 1 quantitatively into staurosporine 2. The same results were observed whenthe parental strain R19/col 15 *H and 13C NMRspectra: see Table 1 .
In Vitro Biological Properties The activity of 1 against different subtypes of protein kinase C was determined by comparison with staurosporine 2 and its TV-benzoyl derivative CGP41 251. The results are compiled in Table 2 . limited to the early steps, specifically the incorporation of tryptophan10). Our own studies of blocked mutants ofa staurosporine producer strain has led to the isolation of the 3'-demethoxy-3'-hydroxy analogue 1. This new metabolite has been shownto be a direct precursor of staurosporine. By co fermentation and bioconversion experiments we have excluded the possibility that 1 is produced by demethylation of the end product by an enzyme which could be repressed in the parental strain. Subsequent experiments have corroborated our conclusion that O-methylation is the final step in the biosynthetic pathway of staurosporine ( Fig. 2) and that mutant M14 (DSM 8325) lacks the O-methylase enzyme required for this step. These data and further information on the isolation and characterization of this enzymewill be published in a separate paper. To date only a few staurosporine analogues carrying a free hydroxy group in the sugar moiety have been isolated from microbial sources, e.g. MLR-52, 514), 615'16) , and RK-1409B, 717). In contrast to the new metabolite 1 none of these compoundscontains a hydroxy group in position 3' while retaining the pharmacologically important aminomethyl group in position 4'. As an inhibitor of protein kinase C, 1 turned out to be less potent than staurosporine itself. However, it showed a higher selectivity against the various subtypes of this enzyme. These in vitro results demonstrated once more that comparatively minor modifications of the staurosporine molecule can have a profound effect on its biological properties. Results of our efforts to modify the activity of 1 by chemical transformation will be reported elsewhere.
